Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug

Patients with renal dysfunction are at a higher risk of cardiovascular disease (CVD), which often shares manifestations with heart failure (HF). Last year, the FDA approved the use of sacubitril-valsartan in patients with HF. This dual-acting agent enhances the functions of natriuretic peptides and...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on investigational drugs Vol. 26; no. 5; p. 651
Main Authors Gervasini, Guillermo, Robles, Nicolas Roberto
Format Journal Article
LanguageEnglish
Published England 04.05.2017
Subjects
Aminobutyrates - adverse effects
Aminobutyrates - pharmacology
Aminobutyrates - therapeutic use
Angiotensin Receptor Antagonists - adverse effects
Angiotensin Receptor Antagonists - pharmacology
Angiotensin Receptor Antagonists - therapeutic use
Animals
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - etiology
Drug Combinations
Heart Failure - drug therapy
Humans
Hypertension - drug therapy
Kidney Diseases - complications
Kidney Diseases - drug therapy
Renin-Angiotensin System - drug effects
Tetrazoles - adverse effects
Tetrazoles - pharmacology
Tetrazoles - therapeutic use
heart failure
valsartan
LCZ696
Sacubitril
renal disease
Online AccessGet more information

Cover

More Information
Summary:Patients with renal dysfunction are at a higher risk of cardiovascular disease (CVD), which often shares manifestations with heart failure (HF). Last year, the FDA approved the use of sacubitril-valsartan in patients with HF. This dual-acting agent enhances the functions of natriuretic peptides and inhibits the renin-angiotensin system. Areas covered: This review summarizes the existing preclinical and clinical studies carried out with sacubitril-valsartan (and other drugs with similar pharmacological mechanisms) in HF and hypertensive patients. We put the focus on the renal data provided by these studies. Data were obtained from English peer-reviewed articles on PubMed and clinical trials registered in ClinicalTrials.gov. Expert opinion: Overall, sacubitril-valsartan might be a promising therapeutic approach in patients with renal dysfunction. Renal conditions with marked CV risk, such as arterionephrosclerosis, could constitute a particular setting where to evaluate the impact of the drug. Nevertheless, large, randomized trials are needed to confirm the beneficial effects and safety profile of the drug in renal patients, as well as to elucidate some concerns observed in HF trials, such as the slight increase in proteinuria.
ISSN:1744-7658
DOI:10.1080/13543784.2017.1317345